SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zirdu who wrote (4497)6/15/1998 9:12:00 PM
From: Bhag Karamchandani  Read Replies (1) of 6136
 
In presenting Phase I AG3304 data : what are the odds of AGPH reporting anecdotal ( individual case) account of trial participants experiencing tumor shrinkage, stablization or better still remission or retardation in the progression of tumor growth?? If the results reflect more than mere safety profiles it would be a major plus for this beleaguered stock. IMHO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News